Aptevo Therapeutics Inc
APVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.98M
Close$
$14.79
712.8% upside
Current Fair Value
712.8% upsideUndervalued by 712.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.98 Million |
|---|---|
| Enterprise Value | $-1,607,920.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-87.27 |
| Beta | 1.61 |
| Outstanding Shares | 1,196,364 |
Return
| Return on Equity | -487.63% |
|---|---|
| Return on Assets | -202.89% |
| Return on Invested Capital | -289.07% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | -0.35 |
| Price to Sales | -1.82 |
| Price to Book Ratio | 0.36 |
| Enterprise Value to Revenue | 7.31 |
| Enterprise Value to EBIT | 0.06 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -2.62 |
| Debt to Equity | 0.7 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-6.01
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-3.71
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.22%▼ 0.85% |
|---|---|
| Total Invested | $224,344▼ 2.31% |
| Investors Holding | 90% |
ESG Score
No data
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO6...